Skip to content
Annika Bansal – Lifestyle
Author:
Arcutis Biotherapeutics, Inc.
Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis
March 5, 2026
Arcutis Management to Present at TD Cowen’s 46th Annual Health Care Conference
March 5, 2026
Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 4, 2026
←
Previous Page
1
2
3